Rivals Investigate Market Entry for Booming Weight-Loss Drugs.

Published Date: 12 Dec 2023

Defying expectations that the weight-loss drug market will be valued at $100 billion by the end of the decade, Novo Nordisk and Eli Lilly have gained an upper hand.

Read Full News

Latest News

Could Childhood Obesity Risk Begin Before Birth?

Emerging evidence links prenatal biology and early-life exposures to later obesity risk, suggesting that prevention may need to begin before excess weight develops.

Novonesis Expects Results From Weight-loss Drug Supplement Study in 2027

Danish biosolutions maker Novonesis expects results in the second half of 2027 from research ⁠with Novo Nordisk into whether microbiome supplements could provide additional...

Prepubertal T1D Onset Tied to Lower Risk for Complications

Children diagnosed with T1D before age 7 may face a lower risk for long-term chronic complications in the first 20 years post-diagnosis than those diagnosed later in childhood.

Celon Pharma's Generic Semaglutide Drug Matches Ozempic in Early Study, Shares Jump

Celon Pharma's experimental semaglutide product Reduzek, a generic alternative ⁠to Novo Nordisk's Wegovy and Ozempic, matched the blockbuster weight-loss ⁠drugs in an...

NICE Supports Weekly Insulin Jab for Type 2 Diabetes

Once-weekly insulin efsitora alfa won NICE backing for adults with type 2 diabetes after trials showed glucose control similar to that with established basal insulins, with fewer injections.

CKD in Diabetes: Fewer New Cases, More Burden in Denmark

Among adults with type 1 and type 2 diabetes in Denmark, the incidence of CKD declined from 2016 to 2024 even as its prevalence rose, and mortality remained substantially higher in those with CKD.

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Latest News

Emerging evidence links prenatal biology and early-life exposures to later obesity risk, suggesting that prevention may need to begin before excess weight develops.

Danish biosolutions maker Novonesis expects results in the second half of 2027 from research ⁠with Novo Nordisk into whether microbiome supplements could provide additional...

Children diagnosed with T1D before age 7 may face a lower risk for long-term chronic complications in the first 20 years post-diagnosis than those diagnosed later in childhood.

Celon Pharma's experimental semaglutide product Reduzek, a generic alternative ⁠to Novo Nordisk's Wegovy and Ozempic, matched the blockbuster weight-loss ⁠drugs in an...

Once-weekly insulin efsitora alfa won NICE backing for adults with type 2 diabetes after trials showed glucose control similar to that with established basal insulins, with fewer injections.

Among adults with type 1 and type 2 diabetes in Denmark, the incidence of CKD declined from 2016 to 2024 even as its prevalence rose, and mortality remained substantially higher in those with CKD.

News All Time

Screening for Confidence Tailors GLP-1 Care

Perceived competence — not other factors — best distinguishes weight-loss success with GLP-1 treatment.

Amylyx Drug Cuts Low Blood Sugar Episodes in Bariatric Surgery Patients in Key Trial

Amylyx Pharmaceuticals' experimental drug sharply reduced dangerously low blood sugar episodes in a late-stage trial of patients who ⁠underwent weight-loss surgery, sending...

Diabetes Drug Curbs Weight Gain in Older People With HIV

Metformin, a common diabetes drug, curbs weight gain in older people with HIV over 96 weeks, but the effect reverses after treatment stops, a trial finds.

Semaglutide and Depression: No Clear Link Found

A meta-analysis finds no significant association between use of semaglutide and risk for depression, although with limited certainty of evidence.

GI Medicine Is a ‘Fantastic Voyage’: AGA President Cryer

Gastroenterologist Byron L. Cryer, MD, discusses mentorship, NSAID research, difficult patient conversations, and why access to care remains a pressing challenge.

Swapping Soda for Diet Drinks May Not Cut T2D Risk

Swapping sugary drinks for diet drinks is linked to an increased risk for type 2 diabetes, particularly among younger adults and those of non-Dutch origin.

Low-Carb Diet Tied to Healthier Target Weight

In women with overweight or obesity, eating lower carbs is linked to a healthier target weight and lower waist circumference, body fat, and visceral fat but not to the A Body Shape Index.

CGM Metrics Can Improve Prognosis Insights Beyond A1c in T1D

In patients with T1D, certain CGM metrics can provide information on the risk for severe hypoglycemia independent of A1c and add predictive value for diabetic ketoacidosis.

Health Round: Most Air Pollution Exposure in U.S. Pregnancies Is From Wildfires, Study Says

We also share a report from cardiologists that suggests you might (or might not) want to check your waist and hip measurements, and a laboratory study with some encouraging...

Prader-Willi Experts Flag Safety Risks Linked to Rare Disease Drug

Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR, citing serious adverse events reported ⁠in patients with the rare genetic...

Role-Play as Patients Helps Docs Manage Diabetes Better

A 1-week, on-site role-play-based program in which physicians simulate patient experiences leads to better A1c control in patients with type 2 diabetes at 6 and 12 months.

Duration and Age Tied to Different Complication Risks in T1D

In patients with childhood onset T1D, a longer diabetes duration is mainly linked to a higher risk for retinopathy, and older age more strongly predicts albuminuria after over 30 years of follow up.

Weekly Somapacitan Effective and Safe in Turner Syndrome

Once-weekly somapacitan is as effective as daily growth hormone in promoting linear growth among treatment-naive girls with Turner syndrome, offering a suitable alternative treatment.

Low-Carb Diets: Modest Wins for Weight, Blood Sugar

Cutting carbs may help adults with overweight or obesity achieve modest weight loss and improve some metabolic markers, but the benefits appear limited and don’t increase with stricter restriction.

Med Op-Ed: Drugs, Obesity, and BMI at a Crossroads

Should the FDA rein in celebrity drug endorsements? Could redefining obesity end up rationing care? And is relying on BMI alone letting patients down?

T2D Medication Patterns Vary by A1c Levels

Type 2 diabetes medication adjustments in older adults vary by A1c levels.

Recommended News For You

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

Sickle Cell Disease Drug Pulled From Global Markets

After two years, a significant left nasal obstruction was finally diagnosed.

Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

Glioblastoma cells can 'unstick' from their neighbors to become more deadly

Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.

enhancing survivors of brain tumors' quality of life.

Recommended Articles For You

Strategic Standards in Hematology for Specialists 

Metabolic Vulnerabilities in Solid Tumor Progression 

Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology 

Understanding Melanoma: From Diagnosis to Healing and Excision in Denver 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: When will individuals be able to receive customized cancer vaccines?

2.

Canadian Group Calls for Earlier Colorectal Cancer Screening

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

5.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

1.

Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer

2.

Clinical Pharmacology of Megakaryocyte Maturation-Targeted Therapeutics

3.

The Benefits and Side Effects of Bortezomib in the Fight Against Cancer 

4.

Personalized Tumor Ecological Landscapes in Oncology

5.

Unmasking the Subtle Symptoms of Colon Cancer

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

2.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

3.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

4.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

5.

Immunotherapy: A New Era in Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot